Filing Summary
Business Context and Reporting Period
HealthCor Catalio Acquisition Corp., a Cayman Islands blank-check company, filed this Form 8-K on December 10, 2021 under Item 8.01. The filing concerns its proposed business combination with Hyperfine, Inc. and Liminal Sciences, Inc., pursuant to a July 7, 2021 Business Combination Agreement.
The SEC declared the related Form S-4 registration statement effective on November 26, 2021, and HealthCor began mailing the definitive proxy statement/prospectus on or about November 30, 2021. The extraordinary general meeting was scheduled for December 21, 2021.
Financial Metrics and Capital Structure
- This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics for Hyperfine, Liminal, or HealthCor.
- Jefferies is entitled to deferred underwriting compensation from HealthCor’s initial public offering upon completion of the business combination.
- Jefferies, Evercore, and Wells Fargo are entitled to customary PIPE-investment fees payable at closing and conditioned on successful completion of the transaction. No fee amounts are disclosed in this filing.
Material Changes Versus the Prior Comparable Period
No period-over-period operating or financial comparison is presented. The material development is the supplementation of the proxy statement/prospectus in response to four shareholder demand letters alleging disclosure deficiencies.
- HealthCor disclosed that it reviewed more than 40 potential business combination opportunities, entered into nondisclosure agreements with 20 companies, and delivered letters of intent to Company A, Company B, Hyperfine, and Liminal.
- The supplemental disclosure clarifies transaction-related compensation payable to the investment banks.
- HealthCor stated that the supplemental disclosures would not affect the scheduled timing of the shareholder meeting.
Guidance, Outlook, Risks, and Unusual Items
HealthCor’s board continued to recommend that shareholders vote in favor of each proposal at the extraordinary general meeting. The company stated that it believed the proxy statement/prospectus complied with applicable law and that the shareholder allegations were without merit, while providing supplemental disclosure to avoid potential litigation, delay, costs, and uncertainty.
Completion of the business combination remained subject to shareholder approval, regulatory approvals, and other closing conditions. Risks identified include failure to close or termination of the agreement, litigation, inability to maintain Nasdaq listing, financing needs, transaction costs, disruption to operations, competition, product-development and commercialization risks, regulatory clearance, manufacturing and supply arrangements, reimbursement and pricing, market adoption of Hyperfine’s Swoop product, COVID-19 impacts, and the combined company’s future financial performance.
Key Facts for Investors to Verify
- Whether HealthCor shareholders approved the proposed business combination at the December 21, 2021 meeting.
- Whether all regulatory and other closing conditions were satisfied and whether the transaction closed.
- The final amount of deferred underwriting compensation and PIPE-investment fees payable at closing.
- Potential effects of the shareholder demand letters and any related litigation or settlement activity.
- Hyperfine’s and Liminal’s actual financial results, cash requirements, financing plans, regulatory status, and commercialization progress, which are not provided in this Form 8-K.